TXG
10x Genomics Inc - Ordinary Shares - Class A

2,726
Loading...
Loading...
News
all
press releases
TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell?
Tempus AI posts 89.6% Q2 revenue growth, raises 2025 sales outlook again, and sees positive adjusted EBITDA ahead. What is the investment outlook?
Zacks·29d ago
News Placeholder
More News
News Placeholder
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface
Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface rank high on efficiency metrics, signaling strong profit potential in volatile markets.
Zacks·2mo ago
News Placeholder
5 Must-Buy Efficient Stocks to Buy Amid Volatile Market Conditions
Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface top an efficiency-driven stock screen.
Zacks·2mo ago
News Placeholder
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·2mo ago
News Placeholder
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates
10x Genomics (TXG) delivered earnings and revenue surprises of +180.00% and +24.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
10x Genomics (TXG) Upgraded to Buy: Here's Why
10x Genomics (TXG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
News Placeholder
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
Zacks·2mo ago
News Placeholder
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
AI momentum and rising demand for digital care put Zacks Medical Info Systems industry stocks like VEEV, TXG and IMDX in focus despite new tariff headwinds.
Zacks·3mo ago
News Placeholder
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet
Zacks·4mo ago
News Placeholder
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
Zacks·5mo ago

Latest TXG News

View

Advertisement|Remove ads.

Advertisement|Remove ads.